Novavax Inc (NVAX)
9.12
-0.23
(-2.46%)
USD |
NASDAQ |
Nov 04, 16:00
9.12
0.00 (0.00%)
Pre-Market: 08:51
Novavax Research and Development Expense (Annual): 737.50M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 737.50M |
| December 31, 2022 | 1.235B |
| December 31, 2021 | 2.535B |
| December 31, 2020 | 747.03M |
| December 31, 2019 | 113.84M |
| December 31, 2018 | 173.80M |
| December 31, 2017 | 168.44M |
| December 31, 2016 | 237.94M |
| December 31, 2015 | 162.64M |
| December 31, 2014 | 94.42M |
| December 31, 2013 | 58.53M |
| December 31, 2012 | 26.91M |
| December 31, 2011 | 18.36M |
| December 31, 2010 | 28.03M |
| Date | Value |
|---|---|
| December 31, 2009 | 25.78M |
| December 31, 2008 | 24.33M |
| December 31, 2007 | 17.60M |
| December 31, 2006 | 11.33M |
| December 31, 2005 | 5.075M |
| December 31, 2004 | 7.369M |
| December 31, 2003 | 10.06M |
| December 31, 2002 | 11.50M |
| December 31, 2001 | 10.78M |
| December 31, 2000 | 9.358M |
| December 31, 1999 | 3.40M |
| December 31, 1998 | 3.40M |
| December 31, 1997 | 2.90M |
| December 31, 1996 | 3.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
113.84M
Minimum
2019
2.535B
Maximum
2021
1.074B
Average
747.03M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Moderna Inc | 4.845B |
| BioCryst Pharmaceuticals Inc | 216.57M |
| Eli Lilly and Co | 9.313B |
| AIM ImmunoTech Inc | 10.94M |